Phosphatidylinositol 3-kinases (PI3Ks) plays an important role in cell growth and proliferation and their dysregulation can lead to metastasis. Among the various isoforms of PI3K, PI3Kα was found to be involved in the progression of multiple cancer types, resulting in its potential to be used as a target for anticancer treatment. Thiazolidin-4-one moiety is widely known for its anticancer effect. However, its inhibitory activity against the enzyme PI3Kα is unexplored. Therefore, our aim is to study the effect of thiazolidine-4-one scaffold on PI3K, especially PI3Kα, and explore its uses as an anticancer agent. Keeping that in focus, we integrated various in-silico screening approaches to identify a potential thiazolidin-4-one moiety-carrying molecule against PI3Kα. A database containing 17,729 compounds with thiazolidine-4-one scaffold was downloaded from Chemdiv and screened initially by docking techniques. The top 10 hits were selected based on extra precision docking results. Alpelisib, an Food and Drug Administration-approved PI3Kα inhibitor, was chosen as the standard. These 10 hits were further subjected to molecular mechanics generalized born surface area (MMGBSA) analysis, where MMGBSA ΔG was calculated, and the top 5 molecules with satisfactory values in comparison to the value of the standard drug were subjected to induced fit docking (IFD). The top 2 hits of IFD were analysed for their absorption, distribution, metabolism, excretion, toxicity properties, and were subjected to a 100 ns molecular dynamics (MDs) simulation, along with the standard drug. From the results of the MD simulation, further filtering out was done using water map analysis, and the molecule that had the best result among the two was subjected to an MD simulation of 500 ns, along with the standard drug. The best molecule and standard drug simulation results were compared to confirm its efficacy as a PI3Kα inhibitor.
Krishnan KP, Mangala Shenoy K, Kini SG, Jeyaprakash RS. Identification of thiazolidin-4-one scaffold-based molecules as PI3Kα inhibitors: Molecular docking, MM/GBSA, IFD, ADMET, water-map analysis, and MD simulations. J Appl Pharm Sci. 2025. Article in Press. http://doi.org/10.7324/JAPS.2025.253482
2. Voutsadakis IA. PI3KCA mutations in uterine cervix carcinoma. J Clin Med. 2021;10(2):220. doi: https://doi.org/10.3390/jcm10020220
3. Rzepecka IK, Tysarowski A. PIK3CA and PIK3R1 mutations in cancer: from the mechanism of activation to PI3K targeted therapies. Oncol Clin Pract. 2024. doi: https://doi.org/10.5603/ocp.101216
4. Jia W, Luo S, Guo H, Kong D. Development of PI3Kα inhibitors for tumor therapy. J Biomol Struct Dyn. 2023;41(17):8587–604. doi: https://doi.org/10.1080/07391102.2022.2132293
5. Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15(1):7–24. doi: https://doi.org/10.1038/nrc3860
6. Bawazir WA, Ahmed NS, Abd El-Karim SS, El-Sayed AF, Anwar MM. New thiazolidin-4-ones as anti-cervical cancer agents targeting EGFR: design, synthesis, and computational studies. Future Med Chem. 2025;17(1):75–91. doi: https://doi.org/10.1080/17568919.2024.2437976
7. Drza? W, Trotsko N. Review of recent advances in thiazolidin-4- one derivatives as promising antitubercular agents (2021–present). Molecules. 2025;30(10):2201. doi: https://doi.org/10.3390/molecules30102201
8. Nayak P, Kachroo M. Design, synthesis and in vitro biological activity of some new 1,3- thiazolidine-4-one derivatives as chemotherapeutic agents using virtual screening strategies. Curr Comput Aided Drug Des. 2021;16(6):757–71. doi: https://doi.org/10.2174/1573409916666200116102359
9. Barreiro, EJ. Ch. 1, Privileged scaffolds in medicinal chemistry: design, synthesis, evaluation. In: Bräse S. The Royal Society of Chemistry; 2015. pp 1–15. doi: https://doi.org/10.1039/9781782622246-00001
10. Gornowicz A, Lesyk R, Czarnomysy R, Holota S, Shepeta Y, Pop?awska B, et al. Multi-targeting anticancer activity of a new 4-thiazolidinone derivative with anti-HER2 antibodies in human AGS gastric cancer cells. Int J Mol Sci. 2023;24(7):6791. doi: https://doi.org/10.3390/ijms24076791
11. Elsisi WI, George RF, Syam YM, Abd-Ellatef GEF, Abd El-Karim SS. Recent achievements in molecular insights, anticancer activities, and comparative structure activity relationships of thiazolidin-4-one derivatives as EGFR inhibitors (2019-present). Bioorg Med Chem. 2025;128:118244. doi: https://doi.org/10.1016/j.bmc.2025.118244
12. Pérez-Sianes J, Pérez-Sánchez H, Díaz F. Virtual screening meets deep learning. Curr Comput Aided Drug Des. 2018;15(1):6–28. doi: https://doi.org/10.2174/1573409914666181018141602
13. da Silva Rocha SFL, Olanda CG, Fokoue HH, Sant’Anna CMR. Virtual screening techniques in drug discovery: review and recent applications. Curr Top Med Chem. 2019;19(19):1751–67. doi: https://doi.org/10.2174/1568026619666190816101948
14. Adelusi TI, Bolaji OQ, Ojo TO, Adegun IP, Adebodun S. Molecular mechanics with generalized born surface area (MMGBSA) calculations and docking studies unravel some antimalarial compounds using heme O synthase as therapeutic target. ChemistrySelect. 2023;8(48):1–8. doi: https://doi.org/10.1002/slct.202303686
15. Hou T, Wang J, Li Y, Wang W. Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model. 2011;51(1):69–82. doi: https://doi.org/10.1021/ci100275a
16. Sirin S, Kumar R, Martinez C, Karmilowicz MJ, Ghosh P, Abramov YA, et al. A Computational approach to enzyme design: predicting ω-aminotransferase catalytic activity using docking and MM-GBSA scoring. J Chem Inf Model. 2014;54(8):2334–46. doi: https://doi.org/10.1021/ci5002185
17. Lauria A, Ippolito M, Almerico AM. Inside the Hsp90 inhibitors binding mode through induced fit docking. J Mol Graph Model. 2009;27(6):712–22. doi: https://doi.org/10.1016/j.jmgm.2008.11.004
18. Sotriffer CA. Accounting for induced-fit effects in docking: what is possible and what is not? Curr Top Med Chem. 2011;11(2):179–91. doi: https://doi.org/10.2174/156802611794863544
19. Wang H, Aslanian R, Madison VS. Induced-fit docking of mometasone furoate and further evidence for glucocorticoid receptor 17α pocket flexibility. J Mol Graph Model. 2008;27(4):512–21. doi: https://doi.org/10.1016/j.jmgm.2008.09.002
20. Borhani DW, Shaw DE. The future of molecular dynamics simulations in drug discovery. J Comput Aided Mol Des. 2012;26(1):15–26. doi: https://doi.org/10.1007/s10822-011-9517-y
21. Higgs C, Beuming T, Sherman W. Hydration site thermodynamics explain SARs for triazolylpurines analogues binding to the A2A receptor. ACS Med Chem Lett. 2010;1(4):160–4. doi: https://doi.org/10.1021/ml100008s
22. Shah B, Sindhikara D, Borrelli K, Leffler AE. Water thermodynamics of peptide toxin binding sites on ion channels. Toxins. 2020;12(10):652. doi: https://doi.org/10.3390/toxins12100652
23. Wang Y, He G, Zloh M, Shen T, He Z. Integrating network pharmacology and computational biology to propose Yiqi Sanjie formula’s mechanisms in treating NSCLC: molecular docking, ADMET, and molecular dynamics simulation. Transl Cancer Res. 2024;13(7):3798–813. doi: https://doi.org/10.21037/tcr-24-972
24. He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6(1):425. doi: https://doi.org/10.1038/s41392-021-00828-5
Year
Month